Salute e Benessere

Alvotech to Report Financial Results for the First Nine Months of 2024 on…

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first nine months of the year ended September 30, 2024, after U.S. markets close on Wednesday, November 13, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Thursday November 14, 2024, at 8:00 am ET (13:00 GMT). Live audio of the conference...
Nasdaq GlobeNewswire
30/10/2024

Tiziana Life Sciences Announces Positive Results from Ozempic and Nasal Anti-CD3…

Key Highlights: Nasal anti-CD3 in combination with semaglutide demonstrates synergistic effects in promoting liver homeostasis in preclinical models of diet-induced obesity.The combination significantly reduces inflammation markers, a key factor in obesity-related metabolic disorders. Figure 1: Nasal anti-CD3 with Low and High Dose semaglutide promote Liver Homeostasis in DIOPBS= Placebo, HFD= High Fat Diet, LD= Low Dose, HD= High Dose, Sema= Semaglutide, aCD3= Study Version of...
Nasdaq GlobeNewswire
30/10/2024

SciBase initiates sales collaboration in Italy

Michelangelo Simonelli, CEO at Kilabs, is spearheading the introduction of Nevisense in Italy Under Simonelli's leadership leveraging on a team of recognized experts in the field such as Alessandro Cappella and Giuseppe Romano, Kilabs is working to integrate Nevisense into clinical practice, offering a more accurate and non-invasive method for early melanoma detection, which could significantly improve patient outcomes in the field of dermatology. This initiative underscores Kilabs' commitment…
PR Newswire
30/10/2024

Blue Earth Therapeutics Ltd announces completion of $76.5M Series A financing to…

"The establishment of PSMA-targeted radiopharmaceuticals as a class of therapy in prostate cancer represents a huge opportunity to improve outcomes for prostate cancer patients. Our new investors share our strong belief that Blue Earth Therapeutics' radiohybrid agents could be a significant improvement over currently approved treatment options," said Fulvio Renoldi Bracco, CEO of Bracco Imaging SpA. "The establishment of PSMA-targeted radiopharmaceuticals as a class of therapy in…
PR Newswire
30/10/2024

Numab Therapeutics Announces Initiation of Phase 1 Clinical Study of NM32…

NM32 is a first-in-class half-life-enhanced T-cell engager targeting ROR1, a tumor associated antigen with broad expression in solid tumors and hematological malignanciesLow molecular weight of NM32 allows to efficiently achieve higher tumor concentrations than larger immunoglobulin G molecules, the current standard format for CD3 engagers HORGEN, Switzerland, Oct.30, 2024(GLOBE NEWSWIRE) -- Numab Therapeutics AG (“Numab”) announced today the start of a Phase 1 clinical trial...
Nasdaq GlobeNewswire
30/10/2024

KFSHRC Leading Healthcare Innovation and Transformation in Saudi Arabia

RIYADH, Saudi Arabia, Oct.30, 2024(GLOBE NEWSWIRE) -- As Saudi Arabia advances its healthcare transformation journey, King Faisal Specialist Hospital & Research Centre (KFSHRC) is reshaping patient care, positioning the Kingdom as a global healthcare hub. With a nearly five-decade legacy in oncology, organ transplantation, and genetic medicine, KFSHRC has elevated healthcare standards and reduced the need for patients to seek treatments abroad.At the Global Health Exhibition 2024,...
Nasdaq GlobeNewswire
30/10/2024

TXN Systems Raises SEK 25 Million Series A to Advance First-in-Class Antibiotic

"There hasn't been a new class of antibiotics developed since 1987, and I'm incredibly excited about the potential of EbsArgent. With its novel mechanism of action on a new target, and extensive testing that has demonstrated its effectiveness against a wide range of drug-resistant pathogens, EbsArgent could give us a valuable new weapon in the fight against antibiotic resistance," Lönn said. "TXN Systems' world-class science is backed by a proven strong team, and we look forward…
PR Newswire
30/10/2024

Telix Partners with Subtle Medical on AI-Enabled SubtlePET™ Software for Faster…

SubtlePET's ability to expedite the imaging process reduces patient wait times and increases comfort, with the patient required to remain motionless under the camera for a shorter period of time, contributing to an overall more positive healthcare experience. Additionally, a shorter scan time for Illuccix will allow healthcare providers to further optimise workflows and resource utilisation. Most importantly for facilities, SubtlePET seamlessly integrates into existing imaging center workflows…
PR Newswire
30/10/2024

EAACI Unveils Groundbreaking Guidelines for IgE-Mediated Food Allergy Management

New evidence-based approach to food allergy management The guide will be presented during the biannual congress of FAAM-EUROBAT 2024 from 21-23 November in Athens, Greece. These guidelines offer a holistic approach to IgE-mediated food allergy management, combining traditional approaches with new treatments that have gathered enough scientific evidence to support their use. The new EAACI guidelines provide clear recommendations for healthcare professionals on how to best manage food...
Nasdaq GlobeNewswire
30/10/2024

Leqembi® revenue totaled JPY 10 billion in the third quarter 2024

BioArctic's report for the third quarter 2024 will be published on November 14 at 08.00 a.m. CET. BioArctic's report for the third quarter 2024 will be published onNovember 14at08.00 a.m. CET. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, onOctober 30, 2024, at11.45 a.m. CET. For further...
PR Newswire
30/10/2024

OKYO Pharma to Present at International Tear Film and Ocular Surface Society…

LONDON and NEW YORK, Oct.30, 2024(GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that it will be presenting at the 10th International Tear Film & Ocular Surface Society Conference in Venice, Italy...
Nasdaq GlobeNewswire
30/10/2024

Hansa Biopharma to Attend Truist Securities BioPharma Symposium

Hansa management will be available for meetings at the conference. If you are interested in meeting with the management team, please contact Hansa Biopharma at [email protected]. Hansa management will be available for meetings at the conference. If you are interested in meeting with the management team, please contact Hansa Biopharma [email protected]. To learn more about Hansa Biopharma see the latest Corporate Presentation here. The latest investor presentation can be...
PR Newswire
30/10/2024

Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in…

"The search for treatments to give hope and help patients and families affected by Alzheimer's disease is what has driven me throughout my scientific career," said Professor Lars Lannfelt. "This field or research is in the midst of a paradigm shift driven by the development of treatments such as lecanemab, which has demonstrated meaningful benefits to patients in the large phase 3 trial Clarity AD using gold standard endpoints. Coupled with the introduction of new diagnostic…
PR Newswire
30/10/2024

Medicover: Interim report July-September 2024

Nine months Nine months REVENUE AND EARNINGS Definition and reconciliation of alternative performance measures are available at www.medicover.com/financial-information.1)LTM: last twelve months ( 1 October 2023-30 September 2024 ) CEO STATEMENT We continue to deliver impressive revenue growth, with organic growth for the quarter exceeding 17%, and with strong organic volume growth in both our reporting segments. All of our key markets are reporting strong growth, and...
PR Newswire
30/10/2024

Largest university hospital in Belgium chooses digital pathology from Sectra to…

UZ Leuven is a leading academic hospital located in Leuven, Belgium, and is one of the largest healthcare providers in the region. It was top-ranked by Newsweek as the best hospital in Belgium and among the top 50 in the world. The 10-year contract for Sectra's digital pathology solution was signed in the second quarter of Sectra's 2024/2025 fiscal year. UZ Leuven is a leading academic hospital located in Leuven,Belgium, and is one of the largest healthcare providers in the region.It was...
PR Newswire
30/10/2024

New data for emapalumab in the treatment of macrophage activation syndrome to be…

"MAS in Still's disease is a severe condition characterised by intense hyperinflammation and multiple organ failure. Those affected, including young children, often experience high fevers, liver and spleen enlargement, severe cytopenias, and neurological symptoms," said Lydia Abad-Franch, MD, Head of Research & Development and Medical Affairs and Chief Medical Officer at Sobi. "The results to be presented at ACR indicate that emapalumab could potentially provide a new…
PR Newswire
30/10/2024

Final Results

DXS INTERNATIONAL PLC(AQSE: DXSP)ANNUAL RESULTSfor the year ended 30 April 2024 The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its audited Final Results for the year ended 30 April 2024. Financial highlights:Revenue decreased by 2.4% to £3,308,359 (2023: £3,391,219). Core recurring revenue model remains resilient.Agreed a...
Nasdaq GlobeNewswire
30/10/2024

Pulsenmore Expands Partnership with Clalit Health Services to Deliver 25,000…

Additionally, Clalit will evaluate the incorporation of Pulsenmore's latest home-based Biophysical Profile (BPP) feature, into its services. The BPP enables medical teams to assess fetal well-being and make timely clinical decisions for high-risk pregnancies. Additionally, Clalit will evaluate the incorporation of Pulsenmore's latest home-based Biophysical Profile (BPP) feature, into its services. The BPP enables medical teams to assess fetal well-being and make timely clinical decisions for...
PR Newswire
30/10/2024

Sandoz reports third-quarter and nine-month 2024 sales

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEStrong third-quarter biosimilars growth of 37% in constant currencies from existing portfolio and recent launchesGenerics growth acceleration driven by EuropeThird-quarter net sales¹ of USD 2.6 billion, up 12% in constant currencies (up 11% in USD)Nine-month net sales of USD 7.6 billion, up 9% in constant currencies (up 8% in USD)Net sales growth guidance increased to high-single digit in...
Nasdaq GlobeNewswire
30/10/2024

Avance Clinical CEO and Asia Director Sign MOUs with Key Clinical Trial Sites in…

Avance Clinical, a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical research services, is proud to announce the signing of three significant Memorandums of Understanding (MOUs) with key Korean clinical sites during KoNECT 2024 conference.Avance Clinical CEO Yvonne Lungershausen and Asia Regional Director Jessica Han, attended the KoNECT conference, and the three clinical sites to sign these partnerships, marking an important...
Nasdaq GlobeNewswire
30/10/2024

Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and…

The collaboration aims to discover and develop molecular glue degrader clinical candidates for priority targets to Biogen.Collaboration leverages Neomorph's leading molecular glue discovery platform and Biogen's deep expertise in Alzheimer's, rare, and immunological diseases. CAMBRIDGE, Mass. and SAN DIEGO, Calif., Oct.29, 2024(GLOBE NEWSWIRE) --BiogenInc. (Nasdaq: BIIB) and Neomorph Inc. announced a research collaboration to discover and develop molecular glue degraders for...
Nasdaq GlobeNewswire
29/10/2024

Endo Announces Successful Term Loan Repricing

Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements including, but not limited to, interest expense savings and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may,"…
PR Newswire
29/10/2024

Novartis Scemblix® FDA approved in newly diagnosed CML, offering superior…

Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies 1-3 Patients on Scemblix also had fewer dose reductions and half the rate of adverse reactions leading to treatment discontinuation 1-3 Nearly 50% of CML patients do not meet efficacy milestones (MMR) with current SoC and...
Nasdaq GlobeNewswire
29/10/2024

SKF divests non-core aerospace operation for USD 220 million

"I'm pleased that we have been able to deliver on our prior promises and successfully reached an agreement to divest this successful but non-core business at accretive multiples. With a new owner, I'm confident that Hanover will continue to provide customers with top quality solutions. Aerospace will remain one of our largest customer industries and we will continue to invest and strengthen our position in core Aerospace segments", says Rickard Gustafson, President and CEO. "I'm…
PR Newswire
29/10/2024
Altri  Comunicati